$7.23
1.97% yesterday
Nasdaq, Jul 17, 10:00 pm CET
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Enanta Pharmaceuticals, Inc. Stock price

$7.23
+0.18 2.55% 1M
+1.98 37.71% 6M
+1.48 25.74% YTD
-8.59 54.30% 1Y
-42.07 85.33% 3Y
-46.30 86.49% 5Y
-42.17 85.36% 10Y
-9.95 57.92% 20Y
Nasdaq, Closing price Thu, Jul 17 2025
+0.14 1.97%
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Key metrics

Basic
Market capitalization
$154.6m
Enterprise Value
$-37.5m
Net debt
positive
Cash
$193.4m
Shares outstanding
21.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.4 | 2.4
EV/Sales
negative | negative
EV/FCF
0.5
P/B
1.7
Financial Health
Equity Ratio
34.2%
Return on Equity
-90.1%
ROCE
-36.9%
ROIC
-105.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$64.5m | $64.3m
EBITDA
$-98.9m | $-92.8m
EBIT
$-102.1m | $-106.6m
Net Income
$-96.4m | $-98.0m
Free Cash Flow
$-82.2m
Growth (TTM | estimate)
Revenue
-11.6% | -5.0%
EBITDA
25.5% | 22.2%
EBIT
24.6% | 12.4%
Net Income
26.8% | 15.5%
Free Cash Flow
27.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-153.5% | -144.4%
EBIT
-158.4%
Net
-149.6% | -152.5%
Free Cash Flow
-127.6%
More
EPS
$-4.5
FCF per Share
$-3.8
Short interest
12.4%
Employees
131
Rev per Employee
$520.0k
Show more

Is Enanta Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Enanta Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

9x Buy
69%
3x Hold
23%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Enanta Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
64 64
12% 12%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 51 51
10% 10%
80%
- Research and Development Expense 115 115
24% 24%
179%
-99 -99
26% 26%
-153%
- Depreciation and Amortization 3.17 3.17
23% 23%
5%
EBIT (Operating Income) EBIT -102 -102
25% 25%
-158%
Net Profit -96 -96
27% 27%
-150%

In millions USD.

Don't miss a Thing! We will send you all news about Enanta Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enanta Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
3 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird's Biotech Discovery Series. A live webcast of t...
Neutral
Business Wire
about one month ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA)...
Neutral
Business Wire
about 2 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025...
More Enanta Pharmaceuticals, Inc. News

Company Profile

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Luly
Employees 131
Founded 1995
Website www.enanta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today